Ispol'zovanie pokazatelya effektivnosti zatrat pri kompleksnoy farmakoekonomicheskoy otsenke dorogostoyashchikh meditsinskikh tekhnologiy. Primer bevatsizumaba

Cite item

Full Text

Ряженов В.В., Горохова С.Г., Саакова М.А., Бунятян Н.Д. Применение показателя эффективности затрат при комплексной фармакоэкономической оценке медицинских технологий. Ведомости научного центра экспертизы средств медицинского применения. 2012; 2: 51-4.
Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 29; 365 (26): 2473-83.
Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 29; 365 (26): 2484-96.
Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 10; 30 (17): 2039-45.
Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. J Clin Oncol 2012; 30 (Suppl.). Abstr. LBA5002.

Supplementary Files

Action

1. JATS XML